WO2009114700A3 - Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion - Google Patents

Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion Download PDF

Info

Publication number
WO2009114700A3
WO2009114700A3 PCT/US2009/036973 US2009036973W WO2009114700A3 WO 2009114700 A3 WO2009114700 A3 WO 2009114700A3 US 2009036973 W US2009036973 W US 2009036973W WO 2009114700 A3 WO2009114700 A3 WO 2009114700A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
neurodegenerative disease
mitochondrial fusion
cell model
identifying inhibitors
Prior art date
Application number
PCT/US2009/036973
Other languages
French (fr)
Other versions
WO2009114700A2 (en
Inventor
Asa Abeliovich
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of WO2009114700A2 publication Critical patent/WO2009114700A2/en
Publication of WO2009114700A3 publication Critical patent/WO2009114700A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

The disclosure provides a method for identifying compounds that may be used in the treatment of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis. The disclosed methods provide a novel mammalian cell-based model of neurodegenerative diseases based on mitochondrial fusion and fission.
PCT/US2009/036973 2008-03-12 2009-03-12 Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion WO2009114700A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3583908P 2008-03-12 2008-03-12
US61/035,839 2008-03-12

Publications (2)

Publication Number Publication Date
WO2009114700A2 WO2009114700A2 (en) 2009-09-17
WO2009114700A3 true WO2009114700A3 (en) 2010-03-18

Family

ID=41065833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036973 WO2009114700A2 (en) 2008-03-12 2009-03-12 Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion

Country Status (1)

Country Link
WO (1) WO2009114700A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946201B2 (en) 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
CN102159219B (en) * 2008-09-16 2015-06-24 圣路易斯大学 Method of enhancing tgf-beta signalling
WO2014059091A2 (en) * 2012-10-12 2014-04-17 Trustees Of Dartmouth College Methods for modulating mitochondrial function via inf2
WO2016111552A1 (en) * 2015-01-06 2016-07-14 권영아 Luterion and separating and culturing methods for same
US11760733B2 (en) 2017-04-23 2023-09-19 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
AU2019427489A1 (en) 2019-01-28 2021-07-22 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
WO2020159797A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168673A1 (en) * 1999-10-06 2002-11-14 Fuller Margaret T. Mitofusins, Fzo homologs and functional derivatives thereof
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US20060084072A1 (en) * 2004-10-20 2006-04-20 University Of Washington Drug targets for the treatment of neurodegenerative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168673A1 (en) * 1999-10-06 2002-11-14 Fuller Margaret T. Mitofusins, Fzo homologs and functional derivatives thereof
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US20060084072A1 (en) * 2004-10-20 2006-04-20 University Of Washington Drug targets for the treatment of neurodegenerative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEWTON ET AL.: "Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis.", PROC NATL ACAD SCI U S A., vol. 103, no. 47, 21 November 2006 (2006-11-21), pages 17955 - 17960 *
POOLE ET AL.: "The PINK1/Parkin pathway regulates mitochondrial morphology.", PROC NATL ACAD SCI U S A., vol. 105, no. 5, 5 February 2008 (2008-02-05), pages 1638 - 43 *

Also Published As

Publication number Publication date
WO2009114700A2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
WO2009114700A3 (en) Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion
WO2012030730A3 (en) Systems and methods for ruled based inclusion of pixel retargeting in campaign management
IL211540A (en) Optical method for the detection of alzheimer's disease
WO2006135622A3 (en) Method and system for determining effectiveness of a compliance program
WO2008024376A3 (en) Method and system for teaching a foreign language
WO2009088891A8 (en) Screening method for selected amino lipid-containing compositions
WO2006044861A3 (en) Pharmaceutical mixture evaluation
WO2008006422A3 (en) Use of ionic liquids or solutions of metal salts in ionic liquids as anti-static agents for plastics
PT3169062T (en) Systems and methods for episode tracking in an interactive media environment
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
WO2011001135A3 (en) Diagnosis and treatment of alzheimer's disease
BRPI0911482A2 (en) USE OF EPOTHYLONE D IN THE TREATMENT OF TAU-ASSOCIATED DISEASES INCLUDING ALZHEIMER DISEASES
WO2007140380A3 (en) Tagging reagents and methods for hydroxylated compounds
WO2009020601A3 (en) Atf4 inhibitors and their use for neural protection, repair, regeneration, and plasticity
WO2013087670A3 (en) Method and device for displaying a charge state of vehicle energy accumulator
WO2010059241A3 (en) Treatment of amyotrophic lateral sclerosis
WO2011029087A3 (en) Methods and systems for personal support and assistance
WO2009013350A3 (en) Imaging medium comprising hyperpolarised 13 c-lactate and use thereof
SMAP200800031A (en) Method for processing research data based on the ternary model
WO2009060829A1 (en) Advertisement presentation method, advertisement presentation system, and program
WO2010129665A3 (en) Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
WO2010041252A3 (en) Use of a cinnamon bark extract for treating amyloid-associated diseases
AU2013292027A8 (en) Vehicle parking
CA2837895C (en) Methods of treating or preventing neurological diseases
WO2009040727A3 (en) Method of differentially diagnosing by spect different types of dementia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09719494

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09719494

Country of ref document: EP

Kind code of ref document: A2